Fermín Sánchez-Guijo Martín-rekin lankidetzan egindako argitalpenak (48)

2022

  1. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

  2. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

  3. Mesenchymal Stromal Cells Combined With Elastin-Like Recombinamers Increase Angiogenesis In Vivo After Hindlimb Ischemia

    Frontiers in Bioengineering and Biotechnology, Vol. 10

  4. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

    CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535

  2. Co-administration of human MSC overexpressing HIF-1α increases human CD34+ cell engraftment in vivo

    Stem Cell Research and Therapy, Vol. 12, Núm. 1

  3. MSCs from polytrauma patients: preliminary comparative study with MSCs from elective-surgery patients

    Stem Cell Research and Therapy, Vol. 12, Núm. 1

2020

  1. Deciphering master gene regulators and associated networks of human mesenchymal stromal cells

    Biomolecules, Vol. 10, Núm. 4

  2. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic

    Frontiers in Medicine, Vol. 7

2019

  1. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

    British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

  2. Splice donor site sgRNAs enhance CRISPR/ Cas9-mediated knockout efficiency

    PLoS ONE, Vol. 14, Núm. 5

  3. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2017

  1. Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis

    PLoS ONE, Vol. 12, Núm. 8

2016

  1. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

  2. Insights into the human mesenchymal stromal/stem cell identity through integrative transcriptomic profiling

    BMC Genomics, Vol. 17, Núm. 1

  3. Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  2. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by BCR-ABL1 fusion gene

    American Journal of Hematology, Vol. 89, Núm. 3, pp. 288-294

  2. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77